Haleema Qamar
Research Scientist Merck & Co
Haleema holds a Ph.D. in electrical engineering from Arizona State University and has a strong background in energy systems engineering. Her research interests include new pulsewidth modulation techniques and controls for hybrid electric vehicle traction inverters and grid-connected photovoltaic inverters. Qamar has been recognized for her contributions to the field, including receiving the Best Paper Presentation Award at the IEEE Applied Power Electronics Conference and Exposition in 2021. Her work at Merck & Co. involves data, AI, and genome sciences, where she is part of the Discovery Biology team. Qamar’s expertise spans cardiac biology, immunology, and fibrosis, and she is also an expert in cardiac tissue engineering, ECM biology, and immune-stromal interactions. Her current role at Merck & Co. allows her to contribute to precision cardiac therapeutics and the development of new treatments through interdisciplinary collaboration and cross-functional expertise.
Seminars
Participate in an interactive, discussion-led session with industry experts to exchange diverse perspectives and solve complex industry challenges within the obesity drug development space without formal presentations.
- Standardizing “High-Quality Weight Loss” (HQWL) indices as a core regulatory endpoint to move beyond “undifferentiated-mass-reduction” as the gold standard for adult and geriatric success, leading to a more nuanced and accurate reflection of metabolic health across the aging spectrum
- Evaluating the ethics and logistics of “metabolic-reset” benchmarks to track the off-treatment persistence of weight stability, building the robust safety database required for universal payer approval and long-term chronic management
- Integrating objective functional outcome assessments (FOAs) regarding “physical-resilience” and “metabolic-reserve” to capture the human impact of treatment, ensuring that drug development remains focused on functional longevity rather than just cosmetic weight loss
